---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-202551"
form_type: "8-K"
ticker: "COYA"
cik: "0001835022"
company_name: "Coya Therapeutics, Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:42:41.008666+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Coya Therapeutics promotes Arun Swaminathan to CEO effective Nov 1, 2024; Howard Berman becomes Executive Chairman

## Summary
- Arun Swaminathan, current CBO, promoted to CEO effective Nov 1, 2024; succeeds Howard Berman.
- Howard Berman resigns as CEO effective Oct 31, 2024, remains as Executive Chairman and director.
- Swaminathan appointed to Board of Directors as Class III director effective immediately.
- Swaminathan led Dr. Reddy's licensing transaction worth up to $700M; executed over $6B in deals.
- Company expects upcoming Alzheimer's data at CTAD24 on Oct 29, 2024; continues progress on COYA 302 in ALS.

## SEC filing metadata
- accession: 0001193125-24-202551
- form_type: 8-K
- ticker: COYA
- cik: 0001835022
- company_name: Coya Therapeutics, Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/d861081d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-202551
- JSON: https://secwatch.observer/filing/0001193125-24-202551.json
- Plain text: https://secwatch.observer/filing/0001193125-24-202551.txt

## Key facts
- Executive change
  Howard Berman resigned as Chief Executive Officer at Coya Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: Dr. Howard Berman, who, on August 16, 2024, notified the Company that he would be resigning as Chief Executive Officer of the Company effective at the close of business on October 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm
- Executive change
  Arun Swaminathan was appointed as Chief Executive Officer at Coya Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Arun Swaminathan, the Company’s Chief Business Officer since April 2023, will serve as Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm
- Executive change
  Arun Swaminathan was appointed as Director at Coya Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: Dr. Swaminathan was also appointed to the Company’s Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm
- Executive change
  Howard Berman was appointed as Executive Chairman at Coya Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Chairman
  source text: After his resignation, Dr. Berman intends to remain a member of the Company’s board of directors (the “Board”) and serve as Executive Chairman of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1835022/000119312524202551/0001193125-24-202551-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.